Aileron Therapeutics (NASDAQ:ALRN) Shares Down 5.6%

Aileron Therapeutics (NASDAQ:ALRN) Shares Down 5.6%

Aileron Therapeutics Inc (NASDAQ:ALRN)’s stock price traded down 5.6% on Monday . The stock traded as low as $0.45 and last traded at $0.51, 603,139 shares traded hands during trading. An increase of 130% from the average session volume of 262,171 shares. The stock had previously closed at $0.54.

Several equities analysts have weighed in on the stock. Zacks Investment Research raised shares of Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a report on Monday, July 8th. William Blair reaffirmed an “outperform” rating on shares of Aileron Therapeutics in a report on Monday, May 6th. Finally, Canaccord Genuity raised shares of Nuvista Energy to a “buy” rating in a report on Tuesday, April 9th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $4.33.

The firm has a fifty day simple moving average of $0.76. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.38.

Aileron Therapeutics (NASDAQ:ALRN) last released its earnings results on Wednesday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.13). As a group, analysts anticipate that Aileron Therapeutics Inc will post -1.11 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Aileron Therapeutics stock. Jennison Associates LLC lifted its stake in Aileron Therapeutics Inc (NASDAQ:ALRN) by 649.6% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,040,255 shares of the company’s stock after buying an additional 1,768,073 shares during the quarter. Jennison Associates LLC owned approximately 13.72% of Aileron Therapeutics worth $3,828,000 at the end of the most recent reporting period. Institutional investors own 29.17% of the company’s stock.

Aileron Therapeutics Company Profile (NASDAQ:ALRN)

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company’s lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

error: Content is protected !!